Published: 2019-07-24

Intralesional triamcinolone acetonide versus platelet rich plasma: a comparative study in the treatment of alopecia areata of scalp

Rahul H. Ranpariya, Sanjeev B. Gupta, Mahendra S. Deora, Prachi V. Agrawal, Rachita Mathur, Aishwarya Raheja


Background: Alopecia areata (AA) is a chronic inflammatory disease characterized by nonscarring hair loss involving any hair-bearing surface of the body. The current therapy for AA is not curative but rather aimed at controlling or limiting the pathogenic process. Corticosteroids are the most popular drugs used, however localized atrophy is a common complication, particularly with triamcinolone. Promoting hair growth by application of autologous blood extracted platelet rich plasma (PRP) is a simple, yet effective procedure. The aim of the study was to evaluate and compare the efficacy of intralesional triamcinolone acetonide (5 mg/ml) with intralesional PRP in the treatment of two different scalp AA patches of same individual.

Methods: A total of 30 patients having ≥2 patches of AA were randomized and given two separate modalities of treatment in two different patches and divided in Group I, treated with intralesional triamcinolone acetonide (5 mg/ml) and Group II, treated with PRP. Interval time between every follow-up was 3 weeks and four such follow-ups were done. Hair regrowth was calculated according to Mac Donald Hull and Norris grading system at every follow-up and was compared with the initial grading.

Results: Group I patches, treated with triamcinolone acetonide have the significantly higher mean grading score than the group II patches, treated with PRP at each follow up.

Conclusions: Intralesional triamcinolone acetonide is more efficacious than intralesional PRP in the treatment of scalp alopecia areata with no recurrences and very few adverse effects like atrophy and hypopigmentation.


Alopecia areata, Triamcinolone acetonide, PRP

Full Text:



Seetharam KA. Alopecia areata: An update. Indian J Dermatol Venereol Leprol. 2013;79:563-75.

Mishra A, Sharma RL, Mishra M. A study of clinical profile of alopecia areata in a tertiary care hospital in western Odisha. IAIM. 2017;4(5):26-30.

Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nature Rev Dis Primers. 2017;3:17011.

Kumaresan M. Intralesional steroids for alopecia areata. Int J Trichol. 2010;2(1):63-5.

Khatu SS, More YE, Gokhale NR, Chavhan DC, Bendsure N. Platelet-rich plasma in androgenic alopecia: Myth or an effective tool. J Cutan Aesthet Surg. 2014;7(2):107-10.

MacDonald Hull S, Norris JF. Diphencyprone in the treatment of long-standing alopecia areata. Br J Dermatol. 1988;119:367-74.

Kuldeep CM, Singhal H, Khare AK, Mittal A, Gupta LK, Garg A. Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata. Int J Trichol. 2011;3:20-4.

Sardesai VR, Prasad S, Agarwal TD. A Study to Evaluate the Efficacy of Various Topical Treatment Modalities for Alopecia Areata. Int J Trichol. 2012;4:265-70.

Bhat YJ, Manzoor S, Khan AR, Qayoom S. Trace element levels in alopecia areata. Indian J Dermatol Venereol Leprol. 2009;75:29-31.

Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol. 1996;35:22-7.

Shumez H, Prasad PVS, Kaviarasan PK, Deepika R. Intralesional platelet rich plasma vs intralesional triamcinolone in thetreatment of alopecia areata: A comparative study. Int J Med Res Health Sci. 2015;4(1):118-22.

Brzezińska-Wcisło L, Wcisło-Dziadecka D, Meszyńska E, Lis-Święty A. New perspectives on the pathogenesis and treatment of hair disorders. Post Nauk Med. 2012;10:800-5.

Al-Mutairi N, Eldin ON. Clinical profile and impact on quality of life: Seven years experience with patients of alopecia areata. Indian J Dermatol Venereol Leprol. 2011;77:489-93.

Muller SA, Winkelmann RK. Alopecia areata. An evaluation of 736 patients. Arch Dermatol 1963;88:290-7.

Cunliffe WJ, Hall R, Stevenson CT, Weighman D. Alopecia areata, thyroid disease and autoimmunity. Br J Dermatol. 1969;81:877-81.

Hegde SP, Naveen KN, Athanikar SB, Reshme P. Clinical and dermatoscopic patterns of alopecia areata: A tertiary care centre experience. Int J Trichol. 2013;5(3):132–6.

Gandhi V, Baruah MC, Bhattacharaya SN. Nail changes in alopecia areata: incidence and pattern. Indian J Dermatol Venereol Leprol. 2003;69:114-5.

Kasumagic-Halilovic E, Prohic A. Nail changes in alopecia areata: frequency and clinical presentation. J Eur Acad Dermatol Venereol. 2009;23:240-1.

Inui S, Nakajima T, Nakagawa K, Itami S. Clinical significance of dermoscopy in alopecia areata: Analysis of 300 cases. Int J Dermatol. 2008;47:688-93.

Abell E, Munro DD. Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol. 1973;88:55–9.

Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol 2009;8:909–12.

Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, et al. A randomized, double-blind, placebo and active-controlled, half-head study to evaluate the effects of platelet rich plasma on alopecia areata. Br J Dermatol. 2013;169(3):690-4.

Greco J, Brandt R. The effects of autologous platelet rich plasma and various growth factors on non-transplanted miniaturized hair. Hair Transplant Forum Int 2009;19:49-50.

Ninama K, Mahajan R, Bilimoria FE, Vaghani A. A clinical study on alopecia areata. Int J Res Dermatol. 2018;4:66-71.

Agrawal P, Jerajani HR, Jindal S. Intralesional platelet rich plasma therapy vs intralesional triamcinolone acetonide for the treatment of alopecia areata. MGM J Med Sci. 2018;5(2):68-75.

Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003;49:96-8.